BioCentury
ARTICLE | Clinical News

Inovio reports interim Phase I data for HBV candidate

March 23, 2018 5:24 PM UTC

Inovio Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800 was well tolerated and generated virus-specific T cells, including CD8+ killer T cells.

The open-label, dose-escalation, international trial enrolled 90 patients with chronic HBV infection to receive INO-1800 alone or in combination with INO-9112, an IL-12-based immune activator, delivered by electroporation. All patients also received standard of care (SOC) oral antiviral therapies...